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Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection Rachanee Cheingsong-Popov, Christina Panagiotidi, Stella Bowcock, Anthony Aronstam, Jane Wadsworth, Jonathan Weber Abstract Objective-To study the contribution of the humoral response to HIV-I at seroconversion to disease outcome after 84 months.
Design-A retrospective longitudinal study. Setting-Two haemophilia centres in the United Kingdom.
Patients-88 Haemophiliac patients infected with HIV-I for whom sera were available from before seroconversion and in whom clinical foliow up data were available.
Results-Kaplan-Meier survival analysis showed a significant difference between a high titre (>1600) p24 antibody response at seroconversion and prolonged time before the development of HIV related disease (p=00008). In contrast, higher titres of antibody to gpl20 at seroconversion (>25 600) correlated with more rapid clinical deterioration (p=0025).
Conclusions-The first humoral response to HIV proteins at seroconversion is associated with clinical outcome; patients with an initial low titre antibody response to the gagp24 protein have a significantly faster rate of progression to CDC stage IV disease.
Patients with a high titre p24 antibody response progress to AIDS more slowly, and these data provide an explanation why p24 antigenaemia is not universally detected in patients with AIDS. It is unclear whether the association between a strong initial p24 antibody response and slower progression of HIV disease is causal and if so whether it is due to viral or host factors.
Introduction
After infection with HIV-I there is a vigorous humoral response to structural and regulatory viral antigens. 8 Antibodies to the env gene products gpl6O/gpl2O and gp4l are produced early followed shortly by antibodies to the gag gene product p24.9 '°B y studying sequential serum samples from infected patients we and other investigators have found that there is an apparent lowering of titre of p24 (gag) antibodies in patients with more rapid progression to HIV related disease (AIDS related complex and AIDS)"'-17 whereas no such change is seen with gp4l (env) antibodies.
Subsequently, it has been repeatedly shown that 50-70% of patients with AIDS have detectable titres of serum p24 antigen whereas only rarely is p24 antigen detectable in asymptomatic patients'82'; detection of p24 antigen before symptomatic disease correlated significantly with prognosis over 27 months.'9 The loss of antibody precedes p24 antigenaemia by [12] [13] [14] [15] [16] [17] [18] months, 22 detector. Seroconversion was defined as the first positive serum sample in the assay performed according to the manufacturer's instructions. The samples had been taken at roughly three monthly intervals, and so the date of seroconversion could be ascertained to within 12 weeks in all cases.
Antigens used in quantitative serology on recombinant HIV antigens-Recombinant env(gp 120) was a fully glycated CD4 binding protein made in Chinese hamster ovary cells (Celltech) and made available through the AIDS directed programme. The p24 protein was a 6-galactosidase fusion protein expressed in Escherichia coli and derived from the HIV-I(CBL-1) isolate. The recombinant nef(p27) was expressed in E coli and based on the HIV-I(BRu) sequence. The specific direct ELISA immunoassays using these recombinant antigens have been described in detail previously. 29 The specificity of these assays was first assessed using a panel of 300 HIV negative sera; eight HIV negative control sera were included on each enzyme immunoassay plate and the cut off calculated as the mean optical density at 492 nm of the negative sera plus three standard deviations. Sera were considered positive if the test optical density was higher than the relative threshold value for that plate.
p24 antigen assay-The commercial p24 antigen assay (DuPont) was used throughout the study according to the manufacturer's instructions.
Statistical analysis -The effect oftitre ofenv(gp 120), gag(p24), and nef(p27) antibodies at the first seropositive serum after infection with HIV on the time to progression of members of the cohort to AIDS and AIDS related diseases (stage IV) was assessed by Kaplan-Meier survival analysis. The significance of difference in time to progression from asymptomatic to stage IV disease was tested by the log rank test with xI approximation. The significance of differences in titres of the first antibody responses was assessed by the Mann-Whitney U test.
Results
The pattern of the antibody response to the gag, env, and nef proteins for the whole cohort over the follow up period is shown in figures la-c. Patients who progressed to stage IV disease over this period differed from those who remained asymptomatic in the pattern of p24(gag) antibody titres (fig la) from the first measurement and subsequently but not in p27(nef) antibody titres (fig 1c) ; the gpl2O(env) antibody titres discriminated only at the first measurement (fig lb) . The first positive sera at seroconversion were therefore analysed in greater detail. Figure 2 shows the median and range of the titres of p24(gag), gpl2O(env), and p27(nef) antibodies for the first positive serum sample after seroconversion from each of the 88 patients in the cohort; values are shown for the 66 Figure 3a shows a significant relation between an initial p24 antibody response and time to progression to stage IV disease; patients with initial titres less than 1600 had significantly shorter times to stage IV disease than those with titres greater than 1600 (p=00008). Figure 3c (p27 antibody) shows a similar pattern to p24 but is less pronounced and is not significant (p=0-128). In figure  3b patients with titres of gpl2O antibody greater than 25600 showed a significantly shorter time to progression to stage IV disease than those with initial titres of gpl2O antibodies of less than 25600 (p=0025). Analysis of the p24 and gpl2O antibody titres for the first seropositive serum by regression coefficient showed that these were independent variables (data not shown).
Discussion
We have shown highly significant associations between p24 and gpl20 antibody titres at seroconversion and the time to development of HIV related disease after infection through the parenteral route. Patients with low p24 and high gpl20 antibody titres develop HIV related disease more rapidly than do those with high p24 and low gpl20 antibody titres and are more likely to develop p24 antigenaemia; we have also shown that the antibodies to p24 and gpl20 are independent variables.
As p24 antigen became detectable in this cohort mainly in the patients with low initial p24 antibody titres it is possible to see how cross sectional studies of HIV infected cohorts have shown conflicting data on the importance of p24 antibody and p24 antigen and why p24 antigenaemia is not universally present in patients with AIDS. Early in the natural history of any cohort low or negative titres of p24 antibodies correlate strongly with the rapid progression of disease. [13] [14] [15] These patients may become antigenaemic early because the low antibody titre enables antigen detection. 30 AIDS later without ever becoming antigenaemic.
The observation that higher titres of p24 antibodies are associated with partial protection from disease progression is compatible with previous studies; these have studied longitudinal cohorts, generally where the date of seroconversion is not known. The difference in p24 antibody response from the time of seroconversion suggests that this phenomenon might have biological importance as well as being statistically significant. The association with protection is incomplete, however, as even the patients with a high p24 antibody titre eventually develop stage IV disease (fig 3a) . The protection is indirect as there is no evidence that monoclonal p24 antibodies can neutralise HIV in vitro,29 although there are reports of possible neutralising antibodies.3' 32 It is impossible to conclude from these data whether the different response to p24 is due to host or viral factors. Possibly, higher quantities of infecting virus might lead to more rapid progression of disease and suppress p24 antibody production. There are several reports of free gpl20 binding CD4 receptors and interfering with T helper cell function and so a high level of circulating virus at seroconversion might depress the cooperation of T helper cells with B cells to produce antibody. [33] [34] [35] In addition, the HLA haplotypes of this population were not determined, and there might be an HLA association with p24 antibody response, such as the HLA-A1, B8, DR3 association with HIV outcome already found.3 37 The association of gpl20 antibody with outcome was significant but probably of less biological importance as it was shown at one time point only; after the seroconversion sample gpl2O antibody failed to predict outcome. Gpl20 antibodies, however, might be capable of enhancing HIV infection by Fc receptor binding mediated by antibody.3 39 The mechanism underlying the association of the p24 antibody response 
